Your browser doesn't support javascript.
loading
Hydrophilic Versus Lipophilic Statin Treatments in Patients With Renal Impairment After Acute Myocardial Infarction.
Kang, Min Hye; Kim, Weon; Kim, Jin Sug; Jeong, Kyung Hwan; Jeong, Myung Ho; Hwang, Jin-Yong; Hur, Seung Ho; Hwang, Hyeon Seok.
Afiliação
  • Kang MH; Division of Nephrology Department of Internal Medicine Kyung Hee University Seoul Republic of Korea.
  • Kim W; Division of Cardiology Department of Internal Medicine Kyung Hee University Seoul Republic of Korea.
  • Kim JS; Division of Nephrology Department of Internal Medicine Kyung Hee University Seoul Republic of Korea.
  • Jeong KH; Division of Nephrology Department of Internal Medicine Kyung Hee University Seoul Republic of Korea.
  • Jeong MH; Department of Internal Medicine and Heart Center Chonnam National University Hospital Gwangju Republic of Korea.
  • Hwang JY; Department of Internal Medicine Gyeongsang National University Hospital Jinju Republic of Korea.
  • Hur SH; Division of Cardiology Keimyung University Medical Center Taegu Republic of Korea.
  • Hwang HS; Division of Nephrology Department of Internal Medicine Kyung Hee University Seoul Republic of Korea.
J Am Heart Assoc ; 11(11): e024649, 2022 06 07.
Article em En | MEDLINE | ID: mdl-35656978
ABSTRACT
Background Hydrophilic and lipophilic statins have similar efficacies in treating coronary artery disease. However, specific factors relevant to renal impairment and different arterial pathogeneses could modify the clinical effects of statin lipophilicity, and create differences in protective effects between statin types in patients with renal impairment. Methods and Results A total of 2062 patients with acute myocardial infarction with an estimated glomerular filtration rate <60 mL/min per 1.73 m2 were enrolled from the Korea Acute Myocardial Infarction Registry between November 2011 and December 2015. The primary end point was a composite of 2-year major adverse cardiac and cerebrovascular events (MACEs) after acute myocardial infarction occurrence. MACEs were defined as all-cause death, recurrent myocardial infarction, revascularization, and stroke. Propensity-score matching and Cox proportional hazards regression were performed. A total of 529 patients treated with hydrophilic statins were matched to 529 patients treated with lipophilic statins. There was no difference in the statin equivalent dose between the 2 statin groups. The cumulative event rate of MACEs, all-cause mortality, and recurrent myocardial infarction were significantly lower in patients treated with hydrophilic statins in the propensity-score matched population (all P<0.05). In the multivariable Cox regression analysis, patients treated with hydrophilic statins had a lower risk for composite MACEs (hazard ratio [HR], 0.70 [95% CI, 0.55-0.90]), all-cause mortality (HR, 0.67 [95% CI, 0.49-0.93]), and recurrent myocardial infarction (HR, 0.40 [95% CI, 0.21-0.73]), but not for revascularization and ischemic stroke. Conclusions Hydrophilic statin treatment was associated with lower risk of MACEs and all-cause mortality than lipophilic statin in a propensity-score matched observational cohort of patients with renal impairment following acute myocardial infarction.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Inibidores de Hidroximetilglutaril-CoA Redutases / Insuficiência Renal / Infarto do Miocárdio Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Am Heart Assoc Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Inibidores de Hidroximetilglutaril-CoA Redutases / Insuficiência Renal / Infarto do Miocárdio Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Am Heart Assoc Ano de publicação: 2022 Tipo de documento: Article